Evidence map›Paper›PMID 38115131›Full record

ReviewJournal of nanobiotechnology2023

Potential therapeutic effects of milk-derived exosomes on intestinal diseases.

Zhifu Cui, Felix Kwame Amevor, Xingtao Zhao, Chunyan Mou, Jiaman Pang, Xie Peng, Anfang Liu, Xi Lan, Lingbin Liu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Zhifu Cui *College of Animal Science and Technology, Southwest University, Chongqing, P. R. China.
Felix Kwame Amevor *Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Sichuan, P. R. China.
Xingtao Zhao *College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Sichuan, P. R. China.
Chunyan MouCollege of Animal Science and Technology, Southwest University, Chongqing, P. R. China.
Jiaman PangCollege of Animal Science and Technology, Southwest University, Chongqing, P. R. China.
Xie PengCollege of Animal Science and Technology, Southwest University, Chongqing, P. R. China.
Anfang LiuCollege of Animal Science and Technology, Southwest University, Chongqing, P. R. China.
Xi LanCollege of Animal Science and Technology, Southwest University, Chongqing, P. R. China. xlan104@swu.edu.cn.
Lingbin LiuCollege of Animal Science and Technology, Southwest University, Chongqing, P. R. China. liulb515@163.com.
Southwest University · CNChengdu University of Traditional Chinese Medicine · CNSichuan Agricultural University · CN

Funding

the Fundamental Research Funds for the Central Universities SWU-KQ22080the Natural Science Foundation of Chongqing 2023NSCQ-MSX1184
6 · The paper itself

Abstract

Exosomes are extracellular vesicles with the diameter of 30 ~ 150 nm, and are widely involved in intercellular communication, disease diagnosis and drug delivery carriers for targeted disease therapy. Therapeutic application of exosomes as drug carriers is limited due to the lack of sources and methods for obtaining adequate exosomes. Milk contains abundant exosomes, several studies have shown that milk-derived exosomes play crucial roles in preventing and treating intestinal diseases. In this review, we summarized the biogenesis, secretion and structure, current novel methods used for the extraction and identification of exosomes, as well as discussed the role of milk-derived exosomes in treating intestinal diseases, such as inflammatory bowel disease, necrotizing enterocolitis, colorectal cancer, and intestinal ischemia and reperfusion injury by regulating intestinal immune homeostasis, restoring gut microbiota composition and improving intestinal structure and integrity, alleviating conditions such as oxidative stress, cell apoptosis and inflammation, and reducing mitochondrial reactive oxygen species (ROS) and lysosome accumulation in both humans and animals. In addition, we discussed future prospects for the standardization of milk exosome production platform to obtain higher concentration and purity, and complete exosomes derived from milk. Several in vivo clinical studies are needed to establish milk-derived exosomes as an effective and efficient drug delivery system, and promote its application in the treatment of various diseases in both humans and animals.

Indexed as

Enterocolitis, NecrotizingExosomesExtracellular VesiclesAnimalsHumansInfant, NewbornIntestinal MucosaMilkDrug deliveryInflammationIntestinal DiseaseMilk-derived exosomeNanocarrier

Identifiers

PMID38115131
PMCPMC10731872
OpenAlexW4390012023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.